Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.

Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.

Item
http://www.wikidata.org/entity/Q31109447
Renal cell carcinoma.Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base.Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review.Checkpoint inhibition: new treatment options in urologic cancer.Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach.Effect of renal embolization in patients with synchronous metastatic renal cell carcinoma: a retrospective comparison of cytoreductive nephrectomy and systemic medical therapy.Role of liver-directed local tumor therapy in the management of hepatocellular carcinoma with extrahepatic metastases: a SEER database analysis.Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival.Treatment of renal cell carcinoma: Current status and future directions.Hospital volume and outcomes of robot-assisted partial nephrectomy.Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.[Should cytoreductive nephrectomy be performed in patients with metastatic renal cell carcinoma and what is the scientific rationale?]A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma.Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.High competing risks minimize real-world utility of adjuvant targeted therapy in renal cell carcinoma: a population-based analysis.Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic Review
P2860

Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.

Item
http://www.wikidata.org/entity/Q31109447
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Survival Analyses of Patients ...... tional Cancer Data Base Study.
@ast
Survival Analyses of Patients ...... tional Cancer Data Base Study.
@en
type
label
Survival Analyses of Patients ...... tional Cancer Data Base Study.
@ast
Survival Analyses of Patients ...... tional Cancer Data Base Study.
@en
prefLabel
Survival Analyses of Patients ...... tional Cancer Data Base Study.
@ast
Survival Analyses of Patients ...... tional Cancer Data Base Study.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Survival Analyses of Patients ...... ational Cancer Data Base Study
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P932